Schneider N G, Olmstead R E, Steinberg C, Sloan K, Daims R M, Brown H V
West Veterans Affairs Medical Center, CA, USA.
Clin Pharmacol Ther. 1996 Nov;60(5):568-75. doi: 10.1016/S0009-9236(96)90153-8.
Buspirone, a non-sedating anxiolytic, has yielded contradictory results in smoking cessation pilot studies and trials. We tested buspirone (n = 51) versus placebo (n = 49) in a placebo-controlled, double-blind trial of smoking cessation. Survival analyses were performed with use of strict abstinence criteria for efficacy (carbon monoxide levels < or = 8 ppm; no self-reported slips to smoking). No treatment differences were observed between active and placebo groups. There were also no differences among "anxiety" level groups formed post hoc from high versus low, pre-quit anxiety test scores. A number of withdrawal symptoms increased significantly after subjects quit smoking for both the active drug and placebo groups, but these symptoms were not relieved by treatment. There appears to be little evidence that buspirone is effective in smoking cessation or in the relief of withdrawal associated with cessation in a general sample. Selecting for generalized anxiety or anxiety related to cessation is suggested for future testing.
丁螺环酮是一种非镇静性抗焦虑药，在戒烟试点研究和试验中得出了相互矛盾的结果。我们在一项戒烟的安慰剂对照双盲试验中，对丁螺环酮（n = 51）与安慰剂（n = 49）进行了测试。采用严格的戒烟标准进行生存分析以评估疗效（一氧化碳水平≤8 ppm；无自我报告的复吸）。活性药物组和安慰剂组之间未观察到治疗差异。根据戒烟前焦虑测试分数高低事后形成的“焦虑”水平组之间也无差异。对于活性药物组和安慰剂组，许多戒断症状在受试者戒烟后显著增加，但这些症状并未因治疗而缓解。几乎没有证据表明丁螺环酮在一般样本中对戒烟或缓解与戒烟相关的戒断有效。建议选择广泛性焦虑或与戒烟相关的焦虑进行未来测试。
